Covaxin for kids: Vital to make vaccine safety & efficacy data public - The Tribune India

Join Whatsapp Channel

Covaxin for kids

Vital to make vaccine safety & efficacy data public

Covaxin for kids

EVEN as the World Health Organisation (WHO) is yet to grant emergency use authorisation to Covaxin, the Covid vaccine manufactured by Hyderabad-based Bharat Biotech, an expert panel of India’s Central Drugs Standard Control Organisation has recommended its restricted use for children and adolescents. - File photo



EVEN as the World Health Organisation (WHO) is yet to grant emergency use authorisation to Covaxin, the Covid vaccine manufactured by Hyderabad-based Bharat Biotech, an expert panel of India’s Central Drugs Standard Control Organisation has recommended its restricted use for children and adolescents. If Covaxin is approved for the purpose by the Drugs Controller General of India (DCGI), the country will move a significant step closer towards starting the vaccination drive for tens of crores of kids in the age group of two to 18 years.

With schools, coaching centres and sports complexes reopening gradually, the need for inoculation of youngsters cannot be overemphasised. The devastating second wave had seen a surge in coronavirus infections among children. There are apprehensions that kids might also turn out to be a high-risk group during the third wave, as and when it strikes. A major challenge will be to build confidence among students and their parents and nip vaccine hesitancy in the bud. Transparency is of the essence. It’s imperative to make vaccine safety and efficacy data public. Indisputable evidence is a must to silence the doubters and naysayers. The WHO nod, which is expected later this month, could be a game-changer as India plans to take its vaccination programme to the next level. However, a setback at this stage will send the Indian authorities back to the drawing board.

Another challenge pertains to the manufacture and supply of Covaxin. Of the 96 crore-plus doses administered so far in India, Covaxin’s contribution has been barely 11 per cent. Bharat Biotech would have to considerably ramp up production to cater to the sizeable population in the youngest category. Striking a balance between the requirements of different age groups won’t be easy. The country has fully vaccinated only about 30 per cent of its adults till date. So, a lot of ground has to be covered to ensure that people most vulnerable to the worst outcomes get protection at the earliest. A calibrated, data-driven approach is the way forward.


Top News

US reacts to Elon Musk's 'backing permanent seat for India’ remark

US reacts to Elon Musk's 'backing permanent seat for India’ remark

Elon Musk had called India not having a permanent seat in th...

Punjab-origin man awaiting deportation because of his illegal entry dies in US hospital

Punjab-origin man awaiting deportation because of his illegal entry to US dies in hospital

On June 29, 2023, he was arrested by US Customs and Border P...

Campaigning wraps up for Phase-I, top leaders go all out on the hustings

Campaigning wraps up for Phase-I, top leaders go all out on the hustings

Roadshows, rallies held across 21 states | 8 Union ministers...

Iranian missiles, drones fired at Israel bore Chinese stamp

Iranian missiles, drones fired at Israel bore Chinese stamp

Its defence firms supplied key components to Tehran


Cities

View All